Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Strong partnerships and technology leadership are positive, but management's reluctance to provide specifics in the Q&A raises concerns. While strategic partnerships and AI integration are promising, the lack of concrete guidance and details, particularly regarding the Sandoz deal and revenue specifics, may temper enthusiasm. Additionally, the market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
Key Financial Performance
Group Revenues EUR 371 million, a 5% decrease versus the first half of 2024. The decline was impacted by a temporary decline in BMS revenues and a persisting soft market in the Discovery & Preclinical Development (D&PD) segment.
D&PD Revenues EUR 269 million, an 11% decline year-over-year. This includes a temporary decline in BMS revenues and a normalized year-on-year decline of 6% in the D&PD segment due to a soft market.
Just - Evotec Biologics Revenues EUR 102.2 million, a 16% increase year-over-year. Growth was driven by excellent performance with non-Sandoz and DOD customers, as well as an 87% growth in the remaining business.
R&D Spending EUR 19 million, a 35% reduction year-over-year from EUR 29.3 million in the first half of 2024. The reduction aligns with a focus on investments most relevant for partners.
Adjusted Group EBITDA Negative EUR 1.9 million. This was driven by a EUR 7.5 million positive contribution from Just - Evotec Biologics, offsetting lower operational leverage in the D&PD segment.
Cost Reduction Over EUR 60 million in 2025, including EUR 30 million from the Priority Reset program. Achieved through lower external spending, hiring restrictions, and a reduction of 600 FTEs since March 2024.
CapEx Spending EUR 19 million in Q2 2025, with a 50% decline year-over-year in the first half of 2025 compared to 2024. This aligns with a move towards a new CapEx base level.
Liquidity EUR 348 million, a decrease of EUR 23 million due to regular lease and debt payments, and a negative FX difference, partially offset by positive net inflow from operating and investing activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Strategy Unveiled: Focus on pioneering drug discovery and development, centering business around core technology and scientific strength.
Molecular Patient Database Expansion: Expanded to include NURTuRE cohort with 3,000 patients, enabling precision medicine and target identification.
Just - Evotec Biologics Growth: Achieved 16% revenue growth YoY, driven by high demand and scalable technology.
Market Challenges: Navigating a complex funding landscape in biotech, with cautious spending in early-stage R&D.
Sandoz Deal: Planned sale of Toulouse site to Sandoz for $300M, including technology license fees and royalties.
Cost Savings: Achieved over $60M in cost reductions, including a 600 FTE reduction since March 2024.
Revenue Decline in D&PD: 11% decline in Discovery & Preclinical Development segment due to temporary effects and market softness.
Asset-Lighter Business Model: Pivoting towards a less capital-intensive model for Just - Evotec Biologics, focusing on technology licensing and partnerships.
Operational Excellence: Implemented a new operating model to simplify structure, reduce complexity, and increase accountability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue decline in Discovery & Preclinical Development (D&PD): The D&PD segment experienced an 11% revenue decline, attributed to a temporary effect in the BMS collaboration and continued softness in the early drug discovery market. This poses a risk to financial performance and operational stability.
Higher negative change orders: The company faced higher negative change orders in the first half of 2025, primarily due to scientific reasons. This volatility could impact revenue predictability and operational planning.
Soft funding landscape in biotech: The funding environment for early-stage R&D remains challenging, with cautious spending behavior among customers. This could limit project flow and revenue growth in the Discovery & Preclinical Development segment.
Cost reduction measures and workforce cuts: The company has reduced its workforce by 600 FTEs since March 2024 and implemented cost-saving measures. While these actions improve financial metrics, they may impact employee morale and operational capacity.
Foreign currency fluctuations: The company anticipates higher foreign currency impacts in the second half of 2025, which could affect financial performance.
Dependence on Sandoz for J.POD Toulouse facility: The planned sale of the J.POD Toulouse facility to Sandoz introduces dependency on a single partner for this asset, which could pose risks if the partnership faces challenges.
Transition to asset-lighter business model: The shift to an asset-lighter model for Just - Evotec Biologics involves risks related to execution and the ability to maintain high-margin revenues while scaling through partnerships.
Economic uncertainties in customer base: Cautious spending behavior among biotech customers, particularly in early-stage R&D, reflects broader economic uncertainties that could impact revenue and project flow.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company confidently confirms its full year 2025 guidance, despite foreign currency fluctuations expected to have a higher impact in the second half. Improved business mix and cost performance are expected to offset these fluctuations.
Midterm Outlook: The company maintains its 2028 aspiration of 8% to 12% revenue CAGR and greater than 20% EBITDA margin. This is supported by differentiated offerings, operating leverage, and continued innovation.
Just - Evotec Biologics (JEB) Growth: JEB continues to outperform with 16% revenue growth year-over-year. The company remains bullish about the prospects of JEB, which is expected to grow further while pivoting towards an asset-lighter business model.
Market Trends and Funding: Signs of a modest recovery in funding for discovery and preclinical research are emerging. Over the coming quarters, a more normalized distribution of funding and project flow is expected to take shape.
Strategic Transaction with Sandoz: The planned sale of the J.POD Biologics manufacturing facility in Toulouse to Sandoz is expected to close in Q4 2025. This transaction will improve Evotec's revenue mix, profit margins, and capital efficiency, with an estimated USD 300 million consideration for the site, plus technology license fees, multiyear development revenues, milestones, and royalties.
Operational Excellence: The company is ahead of plan in achieving cost-saving targets, with over EUR 60 million in cost reductions planned for 2025. This includes a EUR 30 million full-year impact from the Priority Reset program.
Technology and Innovation: Evotec is expanding its molecular patient database to include new disease areas such as women's health and obesity. This expansion is expected to catalyze new strategic collaborations and enhance value creation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much of the recovery in the balance between early-stage and late-stage funding is built into the guidance for 2025?
A:Management stated that the recovery of VC funding is not expected to translate into a second-half impact. They are planning for similar dynamics in the second half as seen in the first half.
Q:Could you provide a breakdown of revenues for the R&D business into transactional, integrated, and large pharma categories?
A:Management did not provide specific details or proportions. They mentioned that the transactional part is shrinking relative to the integrated and large partnership portions, which have been growing in size over the last few years. They aim to improve the transactional side with a more bespoke commercial setup.
Q:Can you provide insights into the value transfer from Evotec to Sandoz in return for the EUR 300 million deal?
A:Management emphasized their strategy and the value of their technology, IP, and capabilities. They mentioned continued revenue flows, milestone payments, and royalties as part of the ongoing revenue streams. However, they avoided providing concrete numbers or specific details.
Q:What trends are driving spending decisions in the D&PD segment, and are customers shifting towards lower-risk indications?
A:Management noted that biotech, especially in the U.S. East Coast, is down, with early-stage biotech spending less than before the pandemic. Customers are making more cautious decisions, and academics are also showing careful spending patterns. Pharma companies show mixed behavior depending on their life cycle stage.
Q:Has there been renewed interest in leveraging AI capabilities, especially given the FDA's push towards computational modeling technologies?
A:Management acknowledged heightened interest in incorporating AI and machine learning into drug discovery. They highlighted their omics-driven platform and proprietary tools, which position them well for advancements in AI-driven drug discovery.
Q:Are customers becoming more price-sensitive, and is there increasing competition in the pricing environment?
A:Management noted that price sensitivity is more evident in the transactional side of the business due to a softer market. However, integrated deals and long-term strategic partnerships are less affected by price competition.
Q:Are there geographic differences in customer behavior and market dynamics?
A:Yes, there are differences. East Asia, particularly China, shows more market traction compared to the U.S. and Europe. Evotec's exposure is more towards Europe and the U.S., which are currently less dynamic than China.
Q:What is the mix of the JEB business in terms of drug production versus high-margin licensing revenue?
A:Management stated that deals currently include a package of licensing, development, and production. They aim to give more weight to individual components in the future but did not provide specific revenue proportions.
Q:What is the rationale for selling the J.POD 2 in Toulouse at this time?
A:Management stated that the sale aligns with their strategy and timing, emphasizing that it is the right decision for their strategic goals.
Q:What proportion of current revenues come from projects in the kidney disease space, and where is this expected to be by 2028?
A:Management did not provide specific revenue proportions but highlighted their investments in omics technologies and partnerships in chronic kidney diseases. They expect this strategy to yield high-value outcomes and continue to grow.
Q:What types of customers are contributing to the broadening of the customer base in the Just business?
A:The customer base includes a mix of small biotechs and large pharma. Growth in the first half was driven significantly by three large pharma companies, with most work being early-stage development and production.
Q:What is the rationale behind the asset-light strategy for the Just business, and does it affect partnerships with early-stage biotechs?
A:Management emphasized that the asset-light strategy does not hinder their ability to provide capacity for biotech companies. They aim to maintain flexibility and continue supporting early-stage biotech partnerships.
Q:What is driving the increase in change orders, and is there a thematic consistency?
A:The increase in change orders is mostly due to scientific reasons and strategic decisions by customers to reallocate funds. Management stated there is no thematic consistency or trend.
Q:What is the expected phasing for Q3 and Q4 in the D&PD and Biologics segments?
A:Management expects the D&PD segment to have similar dynamics in the second half as in the first half. The Just business is expected to see significant growth in the second half, with a strong contribution in Q4.
Q:Is the Sandoz deal being renegotiated, or is it just the sale of the asset?
A:Management described the Sandoz arrangement as a holistic arrangement moving to a new chapter, implying some level of renegotiation but did not provide specific details.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or specific details for several questions, including the breakdown of R&D revenues, the value transfer specifics in the Sandoz deal, and the proportion of revenues from kidney disease projects. They also refrained from discussing customer deals in detail and did not provide concrete numbers for certain strategic decisions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG
Biologics leverage
CEO
Conference
DOD
DPD segment
Discovery Preclinical
ESG
Head
Hitchin CFO
Instructions conference
Member
Preclinical Development
Priority Reset
Research Division
Volker Braun
behavior
challenge
change order
complexity
core
cost reduction
customer base
decrease
distribution
excellence
flow line
focus
inflow
life
molecule
path
project
revenue DPD
revenue EUR
spending EUR
vision segment
EVO Transcript
Evotec SE (EVO) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals a mixed performance with negative revenue growth and gross margin challenges, countered by optimistic guidance and strategic partnerships. Liquidity remains stable, and management expresses confidence in achieving guidance, but lacks specificity in quarterly forecasts. The market cap suggests moderate sensitivity to news, leading to a neutral prediction for stock price movement over the next two weeks.
Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Unknown4-8
The earnings report shows mixed signals: strong growth in Just-Evotec Biologics and EBITDA, but a decline in overall segment revenues and R&D spending. The Q&A reveals optimism for non-Sandoz revenues and AI adoption, but concerns about BMS revenue decline and lack of clarity on clinical plans. The market cap suggests moderate reactions to these mixed signals, resulting in a neutral stock price prediction.
Evotec SE (EVO) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call summary reveals several negative aspects: a 7% decline in group revenues, negative EBITDA, and economic uncertainties. The Q&A highlights concerns about market recovery, profitability, and management's unclear responses. Despite some positive aspects like JEB growth and strategic transactions, the overall sentiment remains negative due to the revenue decline and financial challenges. The market cap indicates a small-cap company, which typically reacts more strongly to negative news, supporting a prediction of a negative stock price movement (-2% to -8%) over the next two weeks.
Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presents a mixed picture. Strong partnerships and technology leadership are positive, but management's reluctance to provide specifics in the Q&A raises concerns. While strategic partnerships and AI integration are promising, the lack of concrete guidance and details, particularly regarding the Sandoz deal and revenue specifics, may temper enthusiasm. Additionally, the market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
EVO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
